嵌合抗原受体
细胞因子释放综合征
淋巴瘤
医学
免疫学
免疫疗法
癌症研究
细胞疗法
白细胞介素12
白细胞介素21
T细胞
细胞
免疫系统
生物
细胞毒性T细胞
体外
生物化学
遗传学
作者
Shaghayegh Khanmohammadi,Nima Rezaei
标识
DOI:10.1080/14712598.2022.2154601
摘要
New methods in cancer immunotherapy, such as chimeric antigen receptor (CAR)-T cells, have shown promising results in destroying malignant cells. However, limitations and side effects of CAR-T cell therapy, such as graft-versus-host disease (GVHD), neurotoxicity, and cytokine release syndrome, have motivated researchers to investigate safer alternative cells like natural killer (NK) cells.NK cells can effectively recognize hematologic malignant cells and destroy them. Many clinical and preclinical studies investigate the efficacy of CAR-NK cells in treating lymphoma and other hematologic malignancies. The results of published clinical trials and preclinical studies have shown that CAR-NK cells could be an appropriate choice for treating lymphoma. In this review, we discuss the characteristics of CAR-NK cells, their role in treating B-cell and T-cell lymphoma, and the challenges faced by using them. We also highlight clinical trials using CAR-NK cells for treating lymphoma.CAR-NK cells have shown promising results in cancer therapy, especially B-cell lymphoma, with a much lower risk for GVHD, cytokine release syndrome, and neurotoxicity than CAR-T cells. Further investigations are required to overcome the obstacles of CAR-NK cell therapy, both generally, and in cancers like T-cell lymphoma.
科研通智能强力驱动
Strongly Powered by AbleSci AI